Dosing and Administration

Dosing and administration of ketamine should be set and adjusted by a licensed clinician, not by a fixed online formula. The right route, starting dose, timing, and monitoring plan depend on the condition being treated, the product used, other medicines, medical history, and how a person responds. Ketamine is used in several forms, while intranasal esketamine, sold as Spravato, has an FDA-approved prescribing program for specific depressive disorders.

This guide explains the questions to bring to a clinician, including how treatment routes differ and why body weight is only one part of dosing decisions. It is educational information, not medical advice.

What does dosing and administration mean?

Dosing is the amount and schedule of medicine prescribed. Administration is how the medicine is given, such as by intravenous infusion, injection, nasal spray, or an oral preparation. These routes are not interchangeable because they differ in absorption, onset, duration, monitoring, and the clinical evidence supporting their use.

The FDA has warned health care professionals about potential risks associated with compounded ketamine nasal spray, including variability in how compounded products are prepared and used. A prescription does not remove the need for an individualized discussion of safety and follow-up.

What is the typical ketamine dose for depression?

There is no universal “typical” dose that readers should use to judge whether their own prescription is right. Published clinical studies and care settings use different protocols, routes, schedules, and patient-selection criteria. A treatment plan may also differ for ketamine and esketamine.

For esketamine, the FDA-approved label sets out product-specific dosing and supervision requirements for approved uses. For racemic ketamine used for depression, practice can vary because treatment for depression is generally outside ketamine's FDA-approved anesthesia indication. The 2017 American Psychiatric Association consensus statement describes the need for careful patient selection, informed consent, monitoring, and follow-up when ketamine is used for mood disorders.

According to the FDA-approved Spravato prescribing information, patients must be monitored for at least 2 hours after administration because of risks including sedation and dissociation.

How can ketamine be administered?

Ketamine may be administered in a supervised medical setting by intravenous infusion or injection. Some clinicians prescribe other formulations, including oral or sublingual preparations, depending on the clinical setting and patient. Esketamine is a nasal spray with a specific FDA-approved Risk Evaluation and Mitigation Strategy, or REMS, program.

The setting matters as much as the route. In-clinic care can include direct observation during and after dosing. At-home prescribing may involve a different workflow for screening, instructions, monitoring, and follow-up. Ask who will be available if you have concerning symptoms, how the prescriber evaluates response, and what activities you should avoid after treatment.

For a closer look at formulation-specific questions, read the ketamine troche dosage patient guide. For general recovery and monitoring questions, see Safety and Side Effects.

Is ketamine dose calculated by body weight?

Body weight may be considered in some protocols, especially in certain supervised medical settings, but it is not a complete dosing rule. A clinician may also consider the route, indication, age, cardiovascular history, psychiatric history, other prescribed medicines, prior response, and adverse effects.

Weight-based calculations should not be recreated from an article or used to compare prescriptions across routes. A number that appears in a research paper may reflect a specific study population and protocol rather than a recommendation for an individual reader.

When might a clinician adjust a dose or schedule?

A clinician may review a plan when symptoms have not improved as expected, adverse effects are difficult to tolerate, a medical condition changes, or another medication is started or stopped. The next step may be an adjustment, a longer observation period, a different schedule, a discussion of alternatives, or no change at all.

Medication interactions deserve a separate review. Bring a complete list of prescription medicines, over-the-counter products, supplements, alcohol use, and cannabis use to the appointment. See Drug Interactions and Contraindications and Ketamine and Benzodiazepines for questions to discuss with a prescriber.

Ketamine and esketamine are not the same treatment

Ketamine is a medication long approved by the FDA as an anesthetic. Esketamine is one component of ketamine and is available as the prescription nasal spray Spravato for specified depressive disorders under its approved labeling. Their approval status, administration requirements, and evidence base differ.

If you are considering esketamine, ask whether the recommendation fits the FDA-approved indication and how REMS observation will work. If you are considering another ketamine formulation, ask what evidence and safeguards support the proposed plan for your situation. You can also review Research and Evidence before your conversation.

Can a dose be too low to be effective?

A person may not notice the hoped-for change at a given point in treatment, but that does not establish that the dose is too low. Depression symptoms can change for many reasons, and a clinician needs to weigh response alongside safety, tolerability, adherence, and the treatment setting. Report what you are experiencing with specific examples rather than trying to determine the next dose yourself.

Keeping brief notes on symptoms, sleep, side effects, and when they occur can make the follow-up conversation more useful. If you are exploring next steps for difficult-to-treat depressionthis guide to treatment-resistant depression next steps may help you prepare questions for a clinician.